After Selling 2 Cardiovascular Companies for Over $1 Billion, Duke Rohlen is Now Hoping to do the Same with Spirox and Advanced Cardiac Therapeutics — Medsider: Learn from MedTech and HealthTech Experts — Overcast

Overcast Podcaster Info Ads Log In

Medsider: Learn from MedTech and HealthTech Experts

After Selling 2 Cardiovascular Companies for Over $1 Billion, Duke Rohlen is Now Hoping to do the Same with Spirox and Advanced Cardiac Therapeutics

May 31, 2016

0:00 -:--

Speed

–1×+++++2×+

Website • Share link • Share link with timestamp